{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"data_sharing_plan":["IPD Sharing (as of October 2021): Yes"],"condition":["Adenocarcinoma","Colorectal Neoplasm","Gastrointestinal Neoplasms","Intestinal Diseases","Gastrointestinal Disease","Digestive System Diseases","Neoplasms","Intestinal Disease","Gastrointestinal Diseases","Rectal Diseases","Colorectal Neoplasms","Digestive System Disease","Intestinal Neoplasms","Colonic Diseases","Digestive System Neoplasms","Digestive System Neoplasm"],"disease":["Adenocarcinoma","Colorectal Neoplasm","Gastrointestinal Neoplasms","Intestinal Diseases","Gastrointestinal Disease","Digestive System Diseases","Neoplasms","Intestinal Disease","Gastrointestinal Diseases","Rectal Diseases","Colorectal Neoplasms","Digestive System Disease","Intestinal Neoplasms","Digestive System Neoplasms","Colonic Diseases","Digestive System Neoplasm"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2275568"],"location":["Cuba"],"study_start_month":["10"],"keyword":["Oxidative Stress","Metastatic colorectal Cancer","Ocoxin Viusid","Antioxidant","Nutritional supplement"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of Ocoxin-Viusid in Metastatic Colorectal Adenocarcinoma","description":"The research product, registered as a nutritional supplement (Ocoxin, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin-Viusid on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin-Viusid it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.","dates":{"creation":"2018-10-15"},"accession":"2275568","cross_references":{"ClinicalTrials___gov":["NCT03559543"]}}